Aneurysmal Subarachnoid Hemorrhage Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

July 15 12:20 2020
Aneurysmal Subarachnoid Hemorrhage Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Delveinsight Business Research
DelveInsight’s “Aneurysmal Subarachnoid Hemorrhage Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage, historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Aneurysmal Subarachnoid Hemorrhage (aSAH) is a serious condition that not just affects the brain, but multiple other organ systems as well. Despite a steady reduction of mortality from acute SAH in recent years, from over half to approximately one-third, this entity is still associated with considerable morbidity and mortality.

Aneurysmal subarachnoid hemorrhage (aSAH) is a worldwide health burden with high fatality and permanent disability rates. These aneurysms, located at the branching point of proximal intracranial arteries, are not uncommon and found in about 2% of the adult population (and even more frequently in those with a family history of aSAH or polycystic kidney disease).

Risk factors for aneurysm rupture include hypertension, smoking, heavy alcohol use, and cocaine abuse. Mortality can be as high as 50%, with 10–20% of patients dying within the first 24 h from cardiac arrhythmias or cerebral herniation.

 

Get FREE sample copy at: 

https://www.delveinsight.com/sample-request/aneurysmal-subarachnoid-hemorrhage-sah-market

Aneurysmal-Subarachnoid-Hemorrhage-Market-Analysis

The Aneurysmal Subarachnoid Hemorrhage market report also covers emerging drugs, current treatment practices, Aneurysmal Subarachnoid Hemorrhage market share of the individual therapies, current and forecasted Aneurysmal Subarachnoid Hemorrhage Market Size from 2017 to 2030 segmented by seven major markets.

The report provides a detailed current Aneurysmal Subarachnoid Hemorrhage treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

 

Aneurysmal Subarachnoid Hemorrhage Market Key Facts

The incident cases of aSAH is more common in females as compared to males.

According to the study conducted by Yamaki et al., the delayed ischemic neurologic deficit (DIND) affects up to 30% of patients with aSAH. Conversely, it is the main preventable cause of poor outcomes in those patients.

As per Francoeur et al., the majority of SAH patients develop angiographic vasoconstriction (up to 70%), and only around 20–30% develop DCI.

 

Key Benefits of Aneurysmal Subarachnoid Hemorrhage Market Report

  • Aneurysmal Subarachnoid Hemorrhage market report provides an in-depth analysis of Aneurysmal Subarachnoid Hemorrhage Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Aneurysmal Subarachnoid Hemorrhage market report will help in developing business strategies by understanding the Aneurysmal Subarachnoid Hemorrhage Market trends & developments, key players and future market competition that will shape and drive the Aneurysmal Subarachnoid Hemorrhage market in the upcoming years.

  • The Aneurysmal Subarachnoid Hemorrhage market report covers Aneurysmal Subarachnoid Hemorrhage current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Aneurysmal Subarachnoid Hemorrhage market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Aneurysmal Subarachnoid Hemorrhage Market

The Aneurysmal Subarachnoid Hemorrhage market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Aneurysmal Subarachnoid Hemorrhage market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Aneurysmal Subarachnoid Hemorrhage market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

 

Aneurysmal Subarachnoid Hemorrhage Epidemiology

The Aneurysmal Subarachnoid Hemorrhage epidemiology section covers insights about historical and current Aneurysmal Subarachnoid Hemorrhage patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Aneurysmal Subarachnoid Hemorrhage Drugs Uptake and Key Market Players

The Aneurysmal Subarachnoid Hemorrhage Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Aneurysmal Subarachnoid Hemorrhage market or expected to get launched in the market during the study period. The analysis covers Aneurysmal Subarachnoid Hemorrhage market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Evgen Pharma, Actelion Pharmaceuticals, etc., are developing therapies for the treatment of patients with Aneurysmal Subarachnoid Hemorrhage (aSAH).

 

Table of Contents

1. Key Insights

2. Executive Summary 

3. Aneurysmal Subarachnoid Hemorrhage Competitive Intelligence Analysis

4. Aneurysmal Subarachnoid Hemorrhage Market Overview at a Glance

5. Aneurysmal Subarachnoid Hemorrhage Disease Background and Overview

6. Aneurysmal Subarachnoid Hemorrhage Patient Journey

7. Aneurysmal Subarachnoid Hemorrhage Epidemiology and Patient Population

8. Aneurysmal Subarachnoid Hemorrhage Treatment Algorithm, Current Treatment, and Medical Practices

9. Aneurysmal Subarachnoid Hemorrhage Unmet Needs

10. Key Endpoints of Aneurysmal Subarachnoid Hemorrhage Treatment

11. Aneurysmal Subarachnoid Hemorrhage Marketed Products

12. Aneurysmal Subarachnoid Hemorrhage Emerging Therapies

13. Aneurysmal Subarachnoid Hemorrhage Seven Major Market Analysis

14. Attribute Analysis

15. Aneurysmal Subarachnoid Hemorrhage Market Outlook (7 major markets)

16. Aneurysmal Subarachnoid Hemorrhage Access and Reimbursement Overview

17. KOL Views on the Aneurysmal Subarachnoid Hemorrhage Market.

18. Aneurysmal Subarachnoid Hemorrhage Market Drivers

19. Aneurysmal Subarachnoid Hemorrhage Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

Related Reports

Aneurysmal Subarachnoid Hemorrhage Pipeline Insights, 2020

Aneurysmal Subarachnoid Hemorrhage Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Aneurysmal Subarachnoid Hemorrhage (SAH) market.

 

Aneurysmal Subarachnoid Hemorrhage Epidemiology Forecast to 2030

DelveInsight’s ‘Aneurysmal Subarachnoid Hemorrhage Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Aneurysmal Subarachnoid Hemorrhage (SAH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

  Categories: